Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression
PLOS One · 2025
DOI: 10.1371/journal.pone.0328698 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Xinlei Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical College of Qingdao University, Qingdao, China. Hauptthemen laut MEDLINE: Forkhead Box Protein M1, Tamoxifen, Drug Resistance, Neoplasm, Breast Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Despite the high sensitivity of estrogen receptor positive (ER + ) breast cancer to endocrine therapy, many patients have primary resistance or develop resistance to endocrine therapies. Acquired resistance to endocrine therapy is a great challenge in the treatment of ER + breast cancer patient. Here we showed that Response Gene to Complement (RGC)-32 expression is higher in breast cancer than paired normal tissues, which was a poor predictive factor. RGC-32 overexpression resulted in tamoxifen resistance, whereas knockdown of RGC-32 in tamoxifen-resistant cells restored tamoxifen sensitivity. Tamoxifen resistance mediated by RGC-32 was shown to be partially dependent on FoxM1 expression. Mechanistically, RGC-32 could activated PI3K signaling pathway, and then enhanced estrogen receptor alpha (ERα) activity. ERα activation is essential for RGC-32-mediated the expression of FoxM1. These data support that targeting RGC-32 could effectively mitigate cancer progression and tamoxifen resistance, offering a complementary therapeutic approach to reduce acquired endocrine resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Medical College of Qingdao University, Qingdao, China.
- Department of Pathology, The 971 Hospital of People's Liberation Army Navy, Qingdao, China.
- Department of Molecular Pathology, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, China.
- The Affiliated Cardiovascular Hospital of Qingdao University, Qingdao, China.
ORCID-Profile: Peng Zhao
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Li, X., Liu, Y., Wang, Z., Bu, X., Wang, Y., Zhang, W., & Zhao, P. (2025). Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression. PLOS One. https://doi.org/10.1371/journal.pone.0328698
Vancouver
Li X, Liu Y, Wang Z, Bu X, Wang Y, Zhang W, et al. Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression. PLOS One. 2025. doi:10.1371/journal.pone.0328698
BibTeX
@article{Li2025,
author = {Li, Xinlei and Liu, Yan and Wang, Zhiqian and Bu, Xiaocui and Wang, Yu and Zhang, Wei and Zhao, Peng},
title = {Response Gene to Complement 32 promotes cell proliferation and tamoxifen resistance in breast cancer via elevated FoxM1 expression},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0328698}
}
EUVIMED